Business Update

Aethlon Medical acquires strategic cancer therapy patent

Published in Lab Law Weekly, December 15th, 2006

Aethlon Medical, Inc., (AEMD) a developer of therapeutic devices for infectious disease, has acquired worldwide rights to a patent submission entitled, "De-repression of anticancer immunity through extracorporeal removal of microvesicular particles."

Under the patent, assigned to Aethlon Medical by London Health Science Center Research, Inc., the Aethlon Hemopurifier would address a significant unmet clinical need in cancer therapy by reducing the presence of tumor-secreted microvesicles that inhibit the immune system from responding in cancer patients.

Microvesicular particles are small enough to be separated from circulation by the Hemopurifier,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2006-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry